170 related articles for article (PubMed ID: 34060360)
1. Removal of N-Linked Glycosylation Enhances PD-L1 Detection in Colon Cancer: Validation Research Based on Immunohistochemistry Analysis.
Xu J; Yang X; Mao Y; Mei J; Wang H; Ding J; Hua D
Technol Cancer Res Treat; 2021; 20():15330338211019442. PubMed ID: 34060360
[TBL] [Abstract][Full Text] [Related]
2. Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3.
Wu S; Shi X; Wang J; Wang X; Liu Y; Luo Y; Mao F; Zeng X
Front Immunol; 2021; 12():561793. PubMed ID: 33717059
[TBL] [Abstract][Full Text] [Related]
3. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
Ji X; Sui L; Song K; Lv T; Zhao H; Yao Q
Cancer Med; 2021 Jul; 10(14):4743-4751. PubMed ID: 34076351
[TBL] [Abstract][Full Text] [Related]
4. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis.
Wang YN; Lee HH; Hsu JL; Yu D; Hung MC
J Biomed Sci; 2020 Jul; 27(1):77. PubMed ID: 32620165
[TBL] [Abstract][Full Text] [Related]
5. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
[No Abstract] [Full Text] [Related]
6. The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma.
Mills AM; Dill EA; Moskaluk CA; Dziegielewski J; Bullock TN; Dillon PM
Am J Surg Pathol; 2018 Feb; 42(2):183-191. PubMed ID: 28914717
[TBL] [Abstract][Full Text] [Related]
7. A comparability study of natural and deglycosylated PD-L1 levels in lung cancer: evidence from immunohistochemical analysis.
Mei J; Xu J; Yang X; Gu D; Zhou W; Wang H; Liu C
Mol Cancer; 2021 Jan; 20(1):11. PubMed ID: 33413365
[TBL] [Abstract][Full Text] [Related]
8. Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy.
Lee HH; Wang YN; Xia W; Chen CH; Rau KM; Ye L; Wei Y; Chou CK; Wang SC; Yan M; Tu CY; Hsia TC; Chiang SF; Chao KSC; Wistuba II; Hsu JL; Hortobagyi GN; Hung MC
Cancer Cell; 2019 Aug; 36(2):168-178.e4. PubMed ID: 31327656
[TBL] [Abstract][Full Text] [Related]
9. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
10. The Negative Impact of Body Mass Index on the Tumor Microenvironment in Colon Cancer: Results of a Prospective Trial.
Flaherty DC; Jalas JR; Sim MS; Stojadinovic A; Protic M; Lee DJ; Bilchik AJ
Ann Surg Oncol; 2018 May; 25(5):1374-1380. PubMed ID: 29532344
[TBL] [Abstract][Full Text] [Related]
11. Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients.
Cedrés S; Ponce-Aix S; Iranzo P; Callejo A; Pardo N; Navarro A; Martinez-Marti A; Gómez-Abecia S; Zucchiatti AC; Sansano I; Enguita AB; Miquel JM; Viaplana C; Dienstmann R; Paz-Ares L; Felip E
Clin Transl Oncol; 2020 Aug; 22(8):1390-1398. PubMed ID: 31916017
[TBL] [Abstract][Full Text] [Related]
12. β-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas.
Rowe M; Krishnan R; Mills A; Ring K
Int J Gynecol Cancer; 2020 Jul; 30(7):993-999. PubMed ID: 32376735
[TBL] [Abstract][Full Text] [Related]
13. RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1.
Burren S; Reche K; Blank A; Galvàn JA; Dawson H; Berger MD; Zlobec I; Lugli A
Pathol Res Pract; 2021 Jul; 223():153486. PubMed ID: 34051513
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
15. Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency.
Li Z; Joehlin-Price AS; Rhoades J; Ayoola-Adeola M; Miller K; Parwani AV; Backes FJ; Felix AS; Suarez AA
Int J Gynecol Cancer; 2018 Jan; 28(1):59-68. PubMed ID: 29053481
[TBL] [Abstract][Full Text] [Related]
16. Loss of DNA mismatch repair proteins in prostate cancer.
Sharma M; Yang Z; Miyamoto H
Medicine (Baltimore); 2020 May; 99(19):e20124. PubMed ID: 32384491
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of the relationship of DNA mismatch repair with clinicopathologic features and prognosis of colon cancer].
Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
Zhonghua Zhong Liu Za Zhi; 2015 Aug; 37(8):591-6. PubMed ID: 26714599
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin.
Faruk M; Ibrahim S; Aminu SM; Adamu A; Abdullahi A; Suleiman AM; Rafindadi AH; Mohammed A; Iliyasu Y; Idoko J; Saidu R; Randawa AJ; Musa HS; Ntekim A; Shah KZ; Abubakar S; Adoke KU; Manko M; Awasum CA
PLoS One; 2021; 16(1):e0245581. PubMed ID: 33465114
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer.
Wang Y; Lin J; Cui J; Han T; Jiao F; Meng Z; Wang L
Oncotarget; 2017 Feb; 8(6):9354-9365. PubMed ID: 28030840
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression in HNPCC-associated colorectal cancer.
Shiraliyeva N; Friedrichs J; Buettner R; Friedrichs N
Pathol Res Pract; 2017 Dec; 213(12):1552-1555. PubMed ID: 29033182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
